




The relative strengths and weaknesses of CTI Biopharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI Biopharma CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 2.7% points. The greatest weakness of CTI Biopharma CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 113% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	80,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,340
Liabilities, Non-Current	14,245
Other Assets	7,136
Other Compr. Net Income	2,792
Other Expenses	3,614
Other Liabilities	1,779
Other Net Income	-7,996
Other Revenues	60,077
Property and Equipment	4,646
Research and Development	86,455
Selling, General and Administrative Expense	56,241

Output Variable	Value in 1000 USD
Assets	92,287
Liabilities	52,364
Expenses	146,310
Revenues	60,077
Stockholders Equity	39,923
Net Income	-94,229
Comprehensive Net Income	-92,833
BaseVar	180,913
ECR before Limited Liability	-8.0%
Economic Capital Ratio	141%